Properties (59)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
Medication
|
| gptkbp:activeDuring |
Cysteamine
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:availability |
Prescription only
|
| gptkbp:clinicalTrials |
Phase 3
Pregnant women Pediatric patients Adult patients Breastfeeding women |
| gptkbp:contraindication |
Dizziness
Mood changes Sleep disturbances Skin rash Liver function abnormalities Hypersensitivity_to_Cysteamine |
| gptkbp:dosageForm |
Capsule
|
| gptkbp:drugInterdiction |
Absorption
Distribution Metabolism Excretion |
| gptkbp:formFactor |
Capsule
|
| gptkbp:hasPopulation |
Adults
Children |
| gptkbp:healthcare |
Important for treatment efficacy
Awareness of side effects Dietary considerations Importance of regular dosing Need for regular follow-up appointments |
| https://www.w3.org/2000/01/rdf-schema#label |
Cystagon
|
| gptkbp:impact |
Lifelong
|
| gptkbp:interactsWith |
Antacids
Vitamin C Iron supplements Other medications affecting kidney function |
| gptkbp:is_monitored_by |
Renal function
Growth parameters Thyroid function |
| gptkbp:lastProduced |
1994
|
| gptkbp:mandates |
Long-term management of cystinosis
|
| gptkbp:manufacturer |
Raptor_Pharmaceuticals
|
| gptkbp:offers |
Varies by pharmacy
|
| gptkbp:packaging |
Bottle
|
| gptkbp:relatedPatent |
Kidney damage
Eye damage Growth retardation |
| gptkbp:route |
Oral
|
| gptkbp:sells |
gptkb:Cystagon
|
| gptkbp:sideEffect |
Diarrhea
Fatigue Nausea Vomiting Headache Abdominal pain Anorexia |
| gptkbp:skills |
100 mg
400 mg |
| gptkbp:storage |
Room temperature
|
| gptkbp:triggerType |
Cysteamine_reduces_cystine_accumulation
|
| gptkbp:usedFor |
Cystinosis
|